Managing Stomach and Digestive Problems in Rett Syndrome — Including Guidance for Those on Trofinetide
A 2024 expert review offers practical guidance for doctors and families on managing common digestive issues in Rett syndrome, including side effects from the newly approved medication trofinetide.
Research Profile
Published: June 1, 2024
Added to SpecialCircle: July 26, 2026
Evidence Level
Review articleResearch Status
More research neededKey takeaways
- •More than 90% of people with Rett syndrome experience digestive (GI) problems such as constipation, diarrhea, vomiting, reflux, and swallowing difficulties.
- •Trofinetide is the first approved medication for Rett syndrome, but it can cause diarrhea and vomiting as side effects.
- •Experts recommend a proactive approach — addressing GI problems early rather than waiting — to help individuals tolerate trofinetide better and improve their quality of life.
- •Many neurologists and pediatricians do not currently rank GI symptom management as a top priority in Rett syndrome care, which this review aims to change.
- •The review is based on both published medical literature and the clinical experience of the expert authors, and addresses what is described as an unmet clinical need.
Source
Expert Review of Gastroenterology & Hepatology · Peer-reviewed study
Read the original sourcePlain-language summary
Rett syndrome is a brain development condition linked to changes in a gene called MECP2. Most people with Rett syndrome also have stomach and digestive problems — things like constipation, reflux, trouble swallowing, and vomiting.
A new medication called trofinetide has been approved to help with Rett syndrome symptoms, but it can make some of these digestive problems worse. A team of experts wrote this review to help doctors and families understand how to manage these digestive issues, whether or not someone with Rett syndrome is taking trofinetide.
They want doctors to take GI symptoms more seriously as part of overall Rett syndrome care.
How it works
Science explained
Rett syndrome is caused by mutations (changes) in the MECP2 gene, which is associated with how the brain and nervous system develop and function. People with Rett syndrome are prone to a wide range of GI problems, including constipation, diarrhea, vomiting, trouble swallowing, and reflux. Trofinetide, the first approved drug for Rett syndrome, improves RTT symptoms overall, but it is also associated with adverse digestive events — primarily diarrhea and vomiting — as side effects.
Why parents may care
If your child or loved one has Rett syndrome, there is a very high chance — over 90% — that they also deal with digestive issues every day, such as painful constipation, reflux, or difficulty swallowing. This review aims to address what experts describe as an unmet clinical need: giving doctors clearer guidance for treating these problems, which could mean better comfort and quality of life.
It is also especially relevant if your family member is on or considering trofinetide.
What this means for daily life
Managing digestive symptoms proactively — rather than waiting until they become severe — could help individuals with Rett syndrome feel more comfortable day to day and make it easier for them to stay on trofinetide if it is helping their Rett syndrome symptoms. Talking to your doctor about a GI management plan may be a helpful next step.
What is still unknown
The review does not establish which specific treatment strategies work best for each GI symptom in Rett syndrome through large clinical trials. It is based partly on general GI literature and the authors' clinical experience, meaning more Rett-specific research is still needed.
It is also unclear how many individuals can successfully continue trofinetide long-term while managing its GI side effects.
Frequently asked questions about Rett Syndrome
Yes — more than 90% of people with Rett syndrome experience gastrointestinal problems, including constipation, diarrhea, vomiting, reflux, swallowing difficulties, and abdominal bloating, according to this 2024 expert review.
Terminology glossary
- Trofinetide
- The first medication approved specifically to treat Rett syndrome; it can improve RTT symptoms but may cause digestive side effects like diarrhea and vomiting.
- MECP2 gene
- The gene whose mutations (changes) cause Rett syndrome by disrupting normal brain and nervous system development.
- Gastrointestinal (GI) comorbidities
- Stomach and digestive system problems — such as constipation, reflux, or swallowing difficulties — that occur alongside another condition like Rett syndrome.
- Dysphagia
- Difficulty swallowing food or liquids, which is a common problem for people with Rett syndrome.
- Gastroparesis
- A condition where the stomach empties food too slowly, which can cause nausea, vomiting, and bloating.
- Gastroesophageal reflux
- When stomach acid flows back up into the food pipe (esophagus), causing discomfort — commonly known as acid reflux or heartburn.
Questions to ask your doctor or therapist
- ?My child has Rett syndrome — should we see a GI specialist to create a proactive plan for managing their digestive symptoms?
- ?If my child starts trofinetide, what strategies can we use ahead of time to prevent or reduce diarrhea and vomiting?
- ?Are there specific signs that my child's GI symptoms are serious enough to adjust or pause trofinetide?
- ?Which digestive problems in Rett syndrome are most important to treat first, and what are the safest options for my child?
⚕️ This research digest is for educational and community support purposes only. It is not medical advice, diagnosis, or treatment. Always speak with a qualified doctor, therapist, or medical professional before making decisions about care.
Related research
Understanding Real-World Use of Trofinetide for Rett Syndrome
This study looked at how people with Rett syndrome in the United States used trofinetide, an FDA-approved treatment, over time.
Understanding Who Receives Trofinetide for Rett Syndrome in the U.S.
A study found that only about one-quarter of eligible individuals with Rett Syndrome received the newly approved medication, Trofinetide, shortly after its approval in the United States.
Update on the NGN-401 Gene Therapy Study
Researchers have finished giving the study treatment to all 25 children in a major trial for a new gene therapy called NGN-401.
Study Investigates Immune System 'Gatekeepers' for Gene Therapy
A new clinical study is checking how many children have antibodies that might block gene therapy from working.
Talk to parents who truly understand
SpecialCircle is a free, private community. Ask questions, share what works, and never feel alone.